<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>23561899</Do_id>
  <Journal>Revue de pneumologie clinique</Journal>
  <Doc_title>[Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer].</Doc_title>
  <Doc_abstract>Crizotinib is a small orally-administered ALK inhibitor for patients with non-small cell lung cancer with EML4-ALK rearrangement (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase). This fusion gene is detected with a break apart fluorescence in situ hybridization (FISH) assay. Phase I to III trials have shown an interesting disease control rate and acceptable tolerability. Crizotinib is available in France under temporary use authorization. New potentially effective therapeutics in ALK-positive NSCLC are being developed.</Doc_abstract>
  <Doc_ChemicalList>Antineoplastic Agents;Drugs, Investigational;EML1-ABL1 fusion protein, human;Oncogene Proteins, Fusion;Protein Kinase Inhibitors;Pyrazoles;Pyridines;crizotinib</Doc_ChemicalList>
  <Doc_meshdescriptors>Adenocarcinoma;Administration, Oral;Antineoplastic Agents;Carcinoma, Non-Small-Cell Lung;Clinical Trials as Topic;Drugs, Investigational;France;Gene Rearrangement;Humans;In Situ Hybridization, Fluorescence;Lung Neoplasms;Molecular Targeted Therapy;Neoplasm Staging;Oncogene Proteins, Fusion;Protein Kinase Inhibitors;Pyrazoles;Pyridines;Tomography, X-Ray Computed</Doc_meshdescriptors>
  <Doc_meshqualifiers>drug therapy;genetics;pathology;administration &amp; dosage;adverse effects;drug therapy;genetics;pathology;administration &amp; dosage;adverse effects;genetics;drug therapy;genetics;pathology;genetics;administration &amp; dosage;adverse effects;administration &amp; dosage;adverse effects;administration &amp; dosage;adverse effects</Doc_meshqualifiers>
</Document>
